candesartan has been researched along with ramiprilat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrends, M; Gres, P; Heusch, G; Post, H; Schulz, R; Weidenbach, R | 1 |
| Büttner, C; Dendorfer, A; Kurz, T; Richardt, D; Richardt, G; Schäfer, U; Wolfrum, S | 1 |
2 other study(ies) available for candesartan and ramiprilat
| Article | Year |
|---|---|
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Hemodynamics; Myocardial Infarction; Ramipril; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Swine; Tetrazoles | 2000 |
Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Male; Myocardial Ischemia; Myocardium; Norepinephrine; Ramipril; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles | 2002 |